These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 1668710

  • 1. Mechanisms of glomerular injury in experimental immune nephritis. II. Effect of a platelet activating factor receptor antagonist in an autologous nephritis model.
    Hruby ZW, Lowry RP, Forbes RD, Blais D.
    Arch Immunol Ther Exp (Warsz); 1991; 39(5-6):575-86. PubMed ID: 1668710
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Mechanisms of glomerular injury in experimental immune nephritis. I. Tumor necrosis factor is released by renal glomeruli of nephritic rats.
    Hruby ZW, Lowry RP.
    Arch Immunol Ther Exp (Warsz); 1991; 39(5-6):563-74. PubMed ID: 1841554
    [Abstract] [Full Text] [Related]

  • 4. Immune reactivity and immunosuppressive intervention (TLI) in experimental nephritis. I. Immunopathologic correlates in the accelerated autologous form of nephrotoxic serum nephritis.
    Lowry RP, Forbes RD, Blackburn JH.
    J Immunol; 1984 Feb; 132(2):1001-6. PubMed ID: 6361128
    [Abstract] [Full Text] [Related]

  • 5. Receptor antagonists of platelet-activating factor do not influence the development of passive Heymann nephritis.
    Salvidio G, Brentjens J, Camussi G.
    J Lipid Mediat; 1991 Feb; 3(2):197-204. PubMed ID: 1665716
    [Abstract] [Full Text] [Related]

  • 6. Immune reactivity and immunosuppressive intervention in experimental nephritis. II. Effect of TLI on the course of two models of nephritis in the inbred rat.
    Lowry RP, Forbes RD, Carpenter CB, Gurley KE, Merrill JP.
    J Immunol; 1984 Feb; 132(2):1007-12. PubMed ID: 6228585
    [Abstract] [Full Text] [Related]

  • 7. Effect of antiproteolytic drugs: epsilon-aminocaproic acid (EACA) and aprotinin on experimental anti-GBM nephritis.
    Hruby Z, Wendycz D, Kopeć W, Czerchawski L, Józefowiak M, Rabczyński J.
    Nephrol Dial Transplant; 1996 Jan; 11(1):32-9. PubMed ID: 8649650
    [Abstract] [Full Text] [Related]

  • 8. Receptor antagonist of platelet activating factor inhibits inflammatory injury induced by in situ formation of immune complexes in renal glomeruli and in the skin.
    Camussi G, Pawlowski I, Saunders R, Brentjens J, Andres G.
    J Lab Clin Med; 1987 Aug; 110(2):196-206. PubMed ID: 2955066
    [Abstract] [Full Text] [Related]

  • 9. Effects of the platelet-activating factor antagonists CV-6209 and CV-3988 on nephrotoxic serum nephritis in the rat.
    Iida H, Fujita M, Izumino K, Asaka M, Entani C, Takata M, Sasayama S.
    Nephron; 1992 Aug; 60(4):471-6. PubMed ID: 1584324
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Platelet-activating factor (PAF) mediation of rat anaphylactic responses to soluble immune complexes. Studies with PAF receptor antagonist L-652,731.
    Doebber TW, Wu MS, Biftu T.
    J Immunol; 1986 Jun 15; 136(12):4659-68. PubMed ID: 3011900
    [Abstract] [Full Text] [Related]

  • 12. The evolution of crescentic nephritis and alveolar haemorrhage following induction of autoimmunity to glomerular basement membrane in an experimental model of Goodpasture's disease.
    Reynolds J, Moss J, Duda MA, Smith J, Karkar AM, Macherla V, Shore I, Evans DJ, Woodrow DF, Pusey CD.
    J Pathol; 2003 May 15; 200(1):118-29. PubMed ID: 12692850
    [Abstract] [Full Text] [Related]

  • 13. Evidence suggesting a role for platelet-activating factor (PAF) in experimental nephrotic syndrome.
    Egido J, Mampaso F, Gómez-Chiarri M, González E, Ortíz A, Lerma JL, Robles A, Braquet P, Hernando L.
    Int J Tissue React; 1990 May 15; 12(4):213-20. PubMed ID: 2178155
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Platelet activating factor (PAF) as a mediator of injury in nephrotoxic nephritis.
    Bertani T, Livio M, Macconi D, Morigi M, Bisogno G, Patrono C, Remuzzi G.
    Kidney Int; 1987 Jun 15; 31(6):1248-56. PubMed ID: 3039232
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Platelet-activating factor receptor antagonist improves renal function and glomerular lesions in renal ablation.
    Thaiss F, Mihatsch MJ, Oberle G, Haberstroh U, Brecht HM, Stahl RA.
    J Lab Clin Med; 1994 Dec 15; 124(6):775-81. PubMed ID: 7798789
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.